BeOne Medicines is a global oncology company focused on discovering, developing, and delivering innovative cancer treatments.
BeOne Medicines, founded in 2010, is a global oncology company specializing in the discovery, development, and delivery of innovative cancer treatments. It employs approximately 12,000 people and operates across six continents, with a focus on making breakthrough medicines accessible worldwide.
The company's internally discovered cancer medicines include BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab), and pamiparib, all of which have received regulatory approval in over 80 countries. These products highlight its capabilities in oncology drug discovery and clinical development.
BeOne Medicines has more than 30 investigational medicines in development and has initiated over 180 clinical trials globally, enrolling over 30,000 patients. This extensive research pipeline underscores its scale and commitment to advancing cancer therapy through rigorous clinical investigation.
